Introduction: Arthrosis represents the progressive degeneration of the joint cartilage, accompanied by the narrowing of the articular space and infl ammation, which aff ects 70% of the population after the age of 60. Research purpose: This paper reviews the opportunity of using proinfl ammatory cytokine inhibitors as a means of stopping the progress of arthrosis. Material and method: As a result to a research into various clinical trial registers (Arthritis Clinical Trials, Clinical Research and Drug Information) and on specialized e-platforms, 5 randomized, multicentric double-blind clinical studies have been identifi ed, which monitored the effi ciency of various biological molecules in the treatment of arthrosis (etanercept, adalimumab, litikizumab, fasinumab and tanezumab). Results: The current pharmacological interventions consist mainly in the prescription of analgesics (acetaminophen, opioid analgesics), non-steroidal and chondroprotective antiinfl ammatories. The proinfl ammatory cytokine inhibitors are already widely used in the infl ammatory joint diseases, such as the rheumatoid polyarthritis. Their introduction into the treatment of arthrosis blocks the disease's etiopathogenic mechanisms. Discussions: Arthrosis physiopathology involves a series of systemic, biological, biochemical factors, molecular and enzymatic processes that generate minimum infl ammation. IL-1b and TNF-α are two major cytokines produced by the synovial cells and chondrocytes, which are involved in the destruction of the cartilage matrix by stimulating the production of proteolytic enzymes (MMP and aggrecanase). Conclusions: The utilisation of proinfl ammatory cytokine inhibitors in arthrosis represents a therapeutic option that requires studies in order to establish whether the introduction of proinfl ammatory cytokine inhibitors in arthrosis therapy might slow down the disease's etiopathogenic mechanisms.
Introduction
Osteoarthritis (OA), one of the most known musculoskeletal disorders, is aff ecting more than 70% of people over 60 years old (1) . For a long time, it was considered only a progressive degenerative joint disease as part of the clinical syndrome, generating pain and invalidity in the elders. The chronic forms of OA are more and more considered as infl ammatory diseases and occur at younger ages.
According to current guidelines for arthrosis therapy, pharmacologic interventions have addressed the symptomatology and mainly consisted in the prescription of analgesics 1 ʺGrigore T. Popaʺ University of Medicine and Pharmacy of Iasi, Romania. 2 (acetaminophen, opioid analgesics), non-steroidal anti-infl ammatories and chondroprotectors (9) . All the therapeutic strategies used nowadays focus on fi ghting the infl ammation. The classical pharmacological therapy, although have analgesic eff ects, does not prevent the progression of degenerative modifi cations of the joint cartilage (10) . The biologic therapy is a fl ourishing area for researches in the fi eld of rheumatoid arthritis (RA) and of ankylosing spondylitis (AS).
Purpose of research: There is lack of knowledge about the physiopathological mechanisms involved in the occurrence or progression of OA, due to the lack of data on the development and maintenance of the cartilage integrity, which is affected in osteoarthritis (2) . The increase of cytokines production and of growth factors production characteristic to OA is usually associated with modifications in other articular structures: degradation of articular cartilage, synovial cells and subchondral bone (2) . The fragments of proteoglycans and collagen from the cartilage surface, occurred due to cracks and erosions, entails the release of these fragments into the synovial liquid. After a stage when the cartilage increases the proteoglycan production in order to repair the degradation, cartilage resorption begins. To the cartilage resorption, the synovial inflammation caused by the cartilage degradation products being released into the synovial liquid is added, the expression of which is the activation of VEGF, NF-kB, COX2, TGF-β, TNF-α, and IL-1β. In this context, this paper reviews the opportunity of using proinflammatory cytokine inhibitors as a means of stopping the progress of arthrosis.
Materials and methods
As a result to a research into various clinical trial registers (Arthritis Clinical Trials, Clinical Research and Drug Information) and on specialized e-platforms, 5 randomized, multicentric double-blind clinical studies (20-24) have been identified, which monitored the efficiency of various biological molecules in the treatment of arthrosis (etanercept, adalimumab, litikizumab, fasinumab and tanezumab).
Results
The prescription of analgesics (acetaminophen, opioid analgesics), nonsteroidal and chondroprotective antiinflammatories represents the current main pharmacological therapy. The proinflammatory cytokine inhibitors have a widespread use in the inflammatory musculoskeletal diseases, such as the rheumatoid polyarthritis. Their introduction into the treatment of arthrosis blocks the disease's etiopathogenic mechanisms.
Only 5 randomized, multicentric doubleblind clinical studies (17) (18) (19) (20) (21) which monitored the efficiency of various biological molecules in the treatment of arthrosis have been identified (Table 1) .
Despite all these, there is no biologically validated therapy for OA (11) . Even if OA has been considered to a large extent a "wearand-tear disease", it involves "low-level" inflammation and the increase in the number of the blood vessels and nerves (12) . This discovery focused the efforts of researchers to develop the biological therapy useful for the treatment of chronic forms of OA and having as targets the pro-inflammatory cytokines and other factors from the articular cartilage, synovial cells and subchondral bone (13) . Nowadays, international fora elaborated arthrosis therapy guidelines. American College of Rheumatology set forth the pharmacologic and non-pharmacologic therapy for the knee, hip and hand arthrosis in 2012 (14) . These recommendations rely on the consensus judgment of experts belonging to various specializations, who processed the available evidence relating to the therapy and assessed the advantages and the potential negative effects of the therapies. Osteoarthritis Research Society International (OARSI) established the nonpharmacologic therapy of the hip and knee arthrosis in 2014. OARSI recommends therapies adequate to each arthrosis phenotype that include kinesio-physiotherapy, intra-articular corticosteroids, weight loss in the obese patient, but also acetaminophen, capsaicin, non-steroidal anti-inflammatory drugs (non-selective or cyclooxygenase-2 selective), and duloxetine. (15, 16) .
American Academy of Orthopaedic Surgeons (AAOS) establishes the nonpharmacologic, pharmacologic and surgical therapy of knee arthrosis in 2014, and EULAR elaborates in 2018 the hand arthrosis therapy guidelines (16) .
Discussions
Arthrosis physiopathological modifications are complex, involving biological and biochemical factors, but also molecular and enzymatic processes that generate minimum inflammation. Proteolytic enzymes (MMP and aggrecanase) activity is stimulated by IL-1β and TNF-α, the main cytokines produced by chondrocytes and by the synovial cells, all these contributing to the degradation of the cartilage matrix. IL-1β may be detected in the synovial liquid and in the cartilage matrix affected by arthrosis. TNF-α seems to have an essential role in causing the inflammation of the synovial membrane and the degradation of the cartilaginous matrix. From these mediators, TNF-α and IL-1β (cataboliceffect cytokines) might stimulate their own production, may stimulate the production of other cytokines (IL-6, IL-8, leukocyte inhibitor) by the chondrocytes and by the cells from the synovial fluid. These stimulate the activity of matrix metalloproteinases and the production of PGE2 that will enhance cartilage degradation (2) (3) (4) (5) . There is important proof to support the key role of IL-1β in the cartilage degradation. IL-1β causes the destruction of cartilage matrix by the release of proteolytic enzymes degradation (MMPs, aggrecanase). IL-1β also block the normal production of the cartilage matrix components (such as type II collagen, aggrecanes) (5) . Concurrently, TNF-α has an essential role in causing inflammation at the level of synovial membrane and in the mediation of the cartilaginous matrix processes. Macrophages produce TNF-α, which is involved in the regulation of chrondrogensis (6) . TNF-α also may cause chondrocyte apoptosis (7) . β-NGF (Nerve growth factor) is a protein identified within the synovial membrane and liquid of the joints affected by both rheumatoid polyarthritis and arthrosis. β-NGF interacts with the tyrosine receptors, thus modifying the vanilloid-like pain receptors' phosphorylation. This protein has initially been identified in the central nervous system and appears to be responsible for the transmission of pain impulses in many diseases (8) .
The physiopathology of arthrosis is associated with a series of systemic modifications, biological parameters and biochemical factors alterations, molecular and enzymatic processes generating inflammation. Although the inflammation is considered to be minimum, the two major cytokines, IL-1β and TNF-α, are produced by the synovial cells and by chondrocytes, which are responsible of the destruction of the cartilage matrix by the stimulation of the proteolytic enzymes' production (MMP and aggrecanase). IL-1b can be detected within the synovial liquid and the extracellular matrix of the joints with arthrosis. TNF-α appears to have an essential role in the inflammatory modifications at the level of synovial membrane and in the destruction of the cartilaginous matrix. The therapeutic use of cytokine inhibitors in OA is based on the effect on variable degrees of inflammation present in OA, especially at the level of synovial membrane, but its role might have been overrated. The synovitis degree may fluctuate in time at the same patient. Patients displaying signs of inflammation, such as warm and swollen joints, large quantities of synovial liquid, and subsequent high pain levels than the patients with the so-called 'dry joint', might be selected for further studies with proinflammatory cytokine inhibiting drugs. The inhibition of a single cytokine may not enough to reduce the inflammation in OA. In the future studies with biological agents, researchers should consider several factors: administration path; number and frequency of injections; patients' selection; disease heterogeneity (including the stage and whether there are atrophic or hypertrophic forms); presence of inflammation. The therapy's risk-benefit ratio is of particular importance. Although the justification exists, the available clinical data are not enough to endorse the current use of biological therapy for patients with OA. The clinical studies' results indicate that the complex mechanisms behind the pain from OA is caused the pro-inflammatory cytokines, but future researches must be done in the direction of disease retarding molecules, or for those acting as analgesics. Despite all these, there is a glimpse of hope for the use of biological agents in the therapy of OA. The pro-inflammatory cytokine inhibitors might represent a new therapeutic option in OA, but further clinical studies are needed. The introduction of proinflammatory cytokine inhibitors as a way of stopping the progress of arthrosis requires the identification of the inclusion criteria for the patients who might benefit from such therapies, the establishment of the optimum moment to initiate the therapy and the optimum administration path (systemic vs intraarticular).
Conclusions
The utilisation of proinflammatory cytokine inhibitors in arthrosis represents a therapeutic option that requires studies in order to establish whether the introduction of proinflammatory cytokine inhibitors in arthrosis therapy might slow down the disease's etiopathogenic mechanisms.
